IDH1 and glioblastoma: Whilst the IDH status has not showed so far to be a significant predictor of PFS or OS in GBM patients treated with LITT (17), it remains unclear why a lower response rate to LITT in the patient's cohort with newly diagnosed GBM, was observed.